PMC9909361_01
Patient transition and chemotherapy.. Abbreviations: mFOLFOX6, oxaliplatin (85 mg/m2), levofolinate (200 mg/m2), and bolus 5-fluorouracil (400 mg/m2) on day 1 followed by 46-hour continuous infusion of 5-fluorouracil (2400 mg/m2); FOLFIRI, irinotecan (150 mg/m2), levofolinate (200 mg/m2), and bolus 5-fluorouracil (400 mg/m2) on day 1 followed by 46-hour continuous infusion of 5-fluorouracil (2400 mg/m2).. Side effect grades were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.. mFOLFOX6/bevacizumab and FOLFIRI/aflibercept regimens were administered once every two weeks without postponement.
cureus-0015-00000033578-i01.jpg
PMC9909361_01_cureus-0015-00000033578-i01.jpg
FIG1
This patient had been administered a total of 20 courses of FOLFIRI/aflibercept therapy, and the peripheral neuropathy, which remained at grade 2-3, showed no signs of improvement (Figure 1).